NCT05469269 Cleveland African American Prostate Cancer Project
| NCT ID | NCT05469269 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Case Comprehensive Cancer Center |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2023-06-09 |
| Primary Completion | 2026-10-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2023-06-09 with a primary completion date of 2026-10-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to test intervention strategies that encourage and support Black or African American men who are 40 and older to complete prostate cancer screening, and specifically to complete a prostate-specific antigen (PSA) test.
Eligibility Criteria
Inclusion Criteria: * ≥40 years old * Self-identify as Black or African American * Have a prostate gland (includes biological males, transwomen) * PSA-naïve or has not received a PSA test in the past 12 months * Has not had a previous prostate cancer diagnosis * English speaking * Ability to consent to study Exclusion Criteria: * Individuals who have had a prostatectomy
Contact & Investigator
Erika Trapl, PhD
PRINCIPAL INVESTIGATOR
Case Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT05469269 clinical trial?
This trial is open to male participants only, aged 40 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05469269 currently recruiting?
Yes, NCT05469269 is actively recruiting participants. Contact the research team at CAAPP@case.edu for enrollment information.
Where is the NCT05469269 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT05469269 clinical trial?
NCT05469269 is sponsored by Case Comprehensive Cancer Center. The principal investigator is Erika Trapl, PhD at Case Comprehensive Cancer Center. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.